compani
recap strong beat sourc beat
limit upsid number
report result our/consensu estim top-line non-gaap ep
came estim y/i
respect midpoint guidanc rais
driven favor payer mix lower-than-expect medicaid util adjust
rebates/discount posit fx impact base trend mngt guidanc
view evolv competit landscap rais estim humalog
trulic alimta trim out-year estim taltz olumi
report posit quarter result alter cautiou view key diabet
franchis face competit headwind challeng outlook key new product
launch fda decis olumi ra discuss reiter neutral
olumi approv comment fda advisori committe
recommend reject approv dose see note disappoint
continu work agenc get dose approv dose key
commerci success superior humira shown dose also
note major olumi sale approv countri dose
call management suggest look persuad fda approv higher dose
highli refractori popul potenti restrict label vs current
propos remain cautiou posit outcom note olumi
accumul patient year data vs submit fda
addit safeti signal detect taltz sale miss attribut
underwhelm result inventori chang given highli competit natur
taltz end-market anticip investor remain highli focus price
environ newli launch agent see limit upsid
estim trulic rewind cardiovascular outcom studi type diabet
top-line press releas like earli mngt comment
extrem import long-term competit trulic state
confid trial appropri power longer durat studi
improv likelihood success outcom
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
timestamp april edtcr eli lilli compani
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
compani april
biopharmaceut compani
diversifi therapeut focu product
focus treat diseas condit
diabet cancer immunolog central nervou
system disord deep pipelin drug
therapeut focu mirror commerci
portfolio found
incorpor indiana top sell
product includ humalog sale
ciali alimta forteo
one highest ep growth name among
us major pharma new product launch
cost cut measur expect drive
neutral believ stock beat
street estim achiev multipl expans
given competit payer headwind
compani diabet categori
risk new brand launch disappoint consensu
verzenio taltz set tough bogey
compani
price object po base blend averag discount
cash flow dcf target multipl appli ep dcf assum
wacc termin growth price-to-earnings multipl base regress analysi
histor us major pharma peer forward month price-to-earnings multipl three-
year-forward ep compound-annual-growth-rate upsid risk po better-than-anticip margin
expans on-going cost-cut program verzenio show meaning
clinic differenti result signific uptak downsid risk po
slower growth trulic rapid biosimilar eros humalog franchis
slower growth new product launch
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
compani april
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
compani april
